Nao Yoneda
Overview
Explore the profile of Nao Yoneda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
117
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Suzuki S, Gi M, Yanagiba Y, Yoneda N, Uehara S, Yokota Y, et al.
J Toxicol Pathol
. 2025 Jan;
38(1):59-67.
PMID: 39839725
Occupational exposure to aromatic amines is a major risk factor for urinary bladder cancer. Our previous studies showed that acetoaceto--toluidine, which is produced using -toluidine as a raw material, promotes...
2.
Jiang C, Li Z, Li P, Ma Y, Seok S, Podguski S, et al.
bioRxiv
. 2024 Oct;
PMID: 39372743
Background & Aims: Unlike protein-coding genes, the majority of human long non-coding RNAs (lncRNAs) lack conservation based on their sequences, posing a challenge for investigating their role in a pathophysiological...
3.
Zerdoug A, Le Vee M, Le Mentec H, Carteret J, Jouan E, Jamin A, et al.
Chemosphere
. 2024 Oct;
366:143474.
PMID: 39369742
Triazole pesticides are widely used fungicides, to which humans are rather highly exposed. They are known to activate drug-sensing receptors regulating expression of hepatic drug metabolizing enzymes and drug transporters,...
4.
Urinary bladder carcinogenic potential of 4,4'-methylenebis(2-chloroaniline) in humanized-liver mice
Suzuki S, Gi M, Kobayashi T, Miyoshi N, Yoneda N, Uehara S, et al.
Toxicol Sci
. 2024 Sep;
202(2):210-219.
PMID: 39287002
Occupational exposure to 4,4'-methylenebis(2-chloroaniline) (MOCA) has been linked to an increased risk of bladder cancer among employees in Japanese plants, indicating its significance as a risk factor for urinary bladder...
5.
Sakai Y, Fukami T, Tokumitsu S, Nakano M, Nakashima S, Higuchi Y, et al.
Drug Metab Pharmacokinet
. 2024 May;
56:101007.
PMID: 38797091
Arylacetamide deacetylase (AADAC) is involved in drug hydrolysis and lipid metabolism. In 23 human liver samples, no significant correlation was observed between AADAC mRNA (19.7-fold variation) and protein levels (137.6-fold...
6.
Jiang C, Li P, Ma Y, Yoneda N, Kawai K, Uehara S, et al.
J Hepatol
. 2023 Dec;
80(4):622-633.
PMID: 38049085
Background & Aims: The human liver transcriptome is complex and highly dynamic, e.g. one gene may produce multiple distinct transcripts, each with distinct posttranscriptional modifications. Direct knowledge of transcriptome dynamics,...
7.
Kamimura H, Uehara S, Yoneda N, Suemizu H
Xenobiotica
. 2023 Nov;
53(8-9):523-535.
PMID: 37938160
Predicting plasma concentration-time profiles of disproportionate metabolites in humans is crucial for evaluating metabolites according to the Safety Testing guidelines. We evaluated Css-MRTpo, an empirical method, using chimeric mice with...
8.
Uehara S, Yasuda M, Higuchi Y, Yoneda N, Kawai K, Suzuki M, et al.
Toxicol Lett
. 2023 Oct;
388:48-55.
PMID: 37806366
SGX523 is a c-Met tyrosine kinase inhibitor that failed in clinical trials because of renal toxicity caused by crystal deposits in renal tubules. SGX523 is metabolized by aldehyde oxidase (AOX)...
9.
Uehara S, Higuchi Y, Yoneda N, Ito R, Takahashi T, Murayama N, et al.
Biochem Biophys Res Commun
. 2023 Apr;
663:132-141.
PMID: 37121123
Primary human hepatocytes (PHHs) have been commonly used as the gold standard in many drug metabolism studies, regardless of having large inter-individual variation. These inter-individual variations in PHHs arise primarily...
10.
Zerdoug A, Le Vee M, Uehara S, Jamin A, Higuchi Y, Yoneda N, et al.
Toxicol In Vitro
. 2023 Apr;
90:105592.
PMID: 37030647
Chimeric mice with humanized liver are thought to represent a sustainable source of isolated human hepatocytes for in vitro studying detoxification of drugs in humans. Because drug transporters are now...